{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T11:30:54Z","timestamp":1766748654415,"version":"3.37.3"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jdiacomp.2024.108741","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T15:48:36Z","timestamp":1711986516000},"page":"108741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Managing cardio-renal-metabolic risk in patients with type 2 diabetes: the role of finerenone"],"prefix":"10.1016","volume":"38","author":[{"given":"Tiziana","family":"Filardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Feraco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Ouvrard-Pascaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Caprio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2024.108741_bb0005","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2024.108741_bb0010","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA Consensus Conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2024.108741_bb0015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/biomedicines11020291","article-title":"Advances in the pharmacological management of diabetic nephropathy: a 2022 international update","volume":"11","author":"Giglio","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jdiacomp.2024.108741_bb0020","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes Diabetes Work Group","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2024.108741_bb0025","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.2337\/dc23-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2024.108741_bb0030","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1016\/j.ijcard.2013.08.060","article-title":"Lipid and blood pressure meta-analysis collaboration group. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?","volume":"168","author":"Nikolic","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jdiacomp.2024.108741_bb0035","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2024.108741_bb0040","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2024.108741_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108553","article-title":"GLP-1 receptor agonists and SGLT2 inhibitors: the need to shed light on their safety risks real dimension and possible mechanisms","volume":"37","author":"G\u00f3mez-Peralta","year":"2023","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jdiacomp.2024.108741_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110726","article-title":"Has the time come to step up to \u201ctriple therapy\u201d for the treatment of diabetic kidney disease?","volume":"201","author":"Patoulias","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jdiacomp.2024.108741_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108630","article-title":"Understanding the mechanisms mediating cardio-renal benefit of empagliflozin in type 2 diabetes mellitus","volume":"37","author":"Patoulias","year":"2023","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jdiacomp.2024.108741_bb0060","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1161\/CIR.0000000000000920","article-title":"Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association","volume":"142","author":"Rangaswami","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2024.108741_bb0065","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2024.108741_bb0070","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2024.108741_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108411","article-title":"Design and rationale of FINE-REAL: a prospective study of finerenone in clinical practice","volume":"37","author":"Desai","year":"2023","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jdiacomp.2024.108741_bb0080","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.numecd.2014.02.013","article-title":"Chronic kidney disease in type 2 diabetes: lessons from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study","volume":"24","author":"Pugliese","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jdiacomp.2024.108741_bb0085","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41581-021-00462-y","article-title":"Trajectories of kidney function in diabetes: a clinicopathological update","volume":"17","author":"Oshima","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jdiacomp.2024.108741_bb0090","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2024.108741_bb0095","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","article-title":"The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling","volume":"93","author":"Barrera-Chimal","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2024.108741_bb0100","doi-asserted-by":"crossref","first-page":"12450","DOI":"10.1096\/fj.202000164R","article-title":"The novel non-steroidal MR antagonist finerenone improves metabolic parameters in high-fat diet-fed mice and activates brown adipose tissue via AMPK-ATGL pathway","volume":"34","author":"Marzolla","year":"2020","journal-title":"FASEB J"},{"key":"10.1016\/j.jdiacomp.2024.108741_bb0105","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2024.108741_bb0110","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s40256-018-00321-5","article-title":"Efficacy and safety of dual blockade of the renin-angiotensin-aldosterone system in diabetic kidney disease: a meta-analysis","volume":"19","author":"Feng","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jdiacomp.2024.108741_bb0115","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/14740338.2022.2130889","article-title":"Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective","volume":"21","author":"Marzolla","year":"2022","journal-title":"Expert Opin Drug Saf"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872724000679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872724000679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T03:51:49Z","timestamp":1714276309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872724000679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1056872724000679"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108741","relation":{},"ISSN":["1056-8727"],"issn-type":[{"type":"print","value":"1056-8727"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing cardio-renal-metabolic risk in patients with type 2 diabetes: the role of finerenone","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108741"}}